Research compounds
Angiotensin 1-7
Ang-(1-7), TXA127
Angiotensin 1-7 is a heptapeptide arm of the renin-angiotensin system that broadly opposes the actions of angiotensin II. It has been investigated for pulmonary and haematological indications without reaching approval.
Also known as: Ang-(1-7), Ang 1-7, TXA127, angiotensin (1-7)
- Status
- Angiotensin 1-7 is a research compound and not approved by the FDA for human use.
- Evidence
- Early human data. Only small or early-phase studies in people so far.
- Half-life
- Approximately 10 to 30 seconds for the native peptide.
- How it's taken
- Subcutaneous or intravenous infusion in the research setting
- Mechanism
- Other
How Angiotensin 1-7 works
Angiotensin 1-7 is generated chiefly by ACE2 acting on angiotensin II, and signals through the Mas receptor. Mas activation produces vasodilation, anti-fibrotic and anti-inflammatory effects, and improved endothelial nitric oxide production — an axis functionally opposite to the classical ACE/angiotensin II/AT1 arm. The ACE2 connection made it a subject of intense interest during COVID-19.
What research has looked at
- The ACE2/Ang-(1-7)/Mas axis is a well-characterised counter-regulatory arm of the renin-angiotensin system, and its existence reframed that system as a balance rather than a single pathway.
- It has been investigated for haematopoietic recovery after chemotherapy and for pulmonary hypertension and fibrosis.
- Anti-fibrotic activity independent of blood-pressure lowering is documented in animal models.
Evidence level: Early human data. Only small or early-phase studies in people so far. These are areas studied or reported, not promised effects.
Reported side effects and risks
- No angiotensin 1-7 product has been approved by any regulator despite several clinical programmes. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy.
- It is degraded within minutes by ACE and other peptidases, so sustained exposure requires infusion or an engineered analogue.
- Effects on blood pressure and on the renin-angiotensin system generally make unsupervised use hazardous, particularly alongside ACE inhibitors or ARBs.
- Much of the enthusiasm during the COVID-19 period was mechanistic speculation that did not translate into demonstrated clinical benefit.
Sources
- PubMed research on angiotensin 1-7 Mas receptor ACE2 · NIH · National Library of Medicine
- DrugBank record for angiotensin 1-7 · DrugBank
- Active clinical trials for angiotensin 1-7 · U.S. National Library of Medicine
Track Angiotensin 1-7 in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Angiotensin 1-7 FAQ
What is Angiotensin 1-7?
Angiotensin 1-7 is a heptapeptide arm of the renin-angiotensin system that broadly opposes the actions of angiotensin II. It has been investigated for pulmonary and haematological indications without reaching approval.
How does Angiotensin 1-7 work?
Angiotensin 1-7 is generated chiefly by ACE2 acting on angiotensin II, and signals through the Mas receptor. Mas activation produces vasodilation, anti-fibrotic and anti-inflammatory effects, and improved endothelial nitric oxide production — an axis functionally opposite to the classical ACE/angiotensin II/AT1 arm. The ACE2 connection made it a subject of intense interest during COVID-19.
Is Angiotensin 1-7 FDA approved?
No. Angiotensin 1-7 is a research compound and not approved by the FDA for human use. Evidence level: early human data. Only small or early-phase studies in people so far.
What is the half-life of Angiotensin 1-7?
Reported half-life: Approximately 10 to 30 seconds for the native peptide.
How is Angiotensin 1-7 taken?
Subcutaneous or intravenous infusion in the research setting.
What side effects have been reported with Angiotensin 1-7?
Reported in the sources: No angiotensin 1-7 product has been approved by any regulator despite several clinical programmes. No regulator has approved it, the human evidence base is limited, and material sold under this name is research chemical supply with unverified identity, purity, sterility and dose accuracy; It is degraded within minutes by ACE and other peptidases, so sustained exposure requires infusion or an engineered analogue; Effects on blood pressure and on the renin-angiotensin system generally make unsupervised use hazardous, particularly alongside ACE inhibitors or ARBs; Much of the enthusiasm during the COVID-19 period was mechanistic speculation that did not translate into demonstrated clinical benefit.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.